December 20, 2018 10:22 AM EST
R&D

On the heels of Chi­na ap­proval, Fi­bro­Gen and As­traZeneca spot­light more pos­i­tive PhI­II da­ta for rox­adu­s­tat

Amber Tong

Days af­ter Fi­bro­Gen and As­traZeneca scored their first ap­proval for rox­adu­s­tat — in Chi­na — the part­ners say they have more Phase III da­ta to sup­port their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times